Oslo, Norway, October 20, 2021-Lytix Biopharma AS, a Norwegian clinical-stage
immuno-oncology company developing oncolytic molecules for cancer treatment,
will present at the Finansavisen Investordagene on Wednesday, October 20, at
15.10 pm CET. 

Please find attached Lytix Biopharma's presentation given by CEO Øystein Rekdal
at the conference.

The presentation is also available on https://www.lytixbiopharma.com/ 

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com


About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic peptide that has
demonstrated superior abilities to induce polyclonal t-cell responses. Lytix
Biopharma was listed at Euronext Growth in Oslo in June 2021, following a
private placement covered by investors such as PBM Capital, a US based,
specialized fund on the biotech industry.